10 results about "Metal Chelator" patented technology

A microorganism engineered to: produce or overproduce auxin; reduce the production of ethylene; produce or overproduce one or more metal chelator molecules; and / or reduce or knockout the production of

Metal chelation compounds and associated coordination complexes are provided. In one aspect, this disclosure provides for a metal chelation compound, the compound having the general structure: D-L-T, wherein D is deferasirox or a derivative thereof, T is triapine or a derivative thereof, and L is a linking group and is a bond, C1-C10 alkyl, C2-C10 alkenyl, or —(C0-C3 alkyl)-R—(C0-C3 alkyl)-, wherein R is aryl, cycloalkyl, or polyethylene glycol.

The present invention discloses a PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group and its preparation, which belongs to the technical fields of radiopharmaceuticals and medical imaging. The general formula of the PSMA-targeted radiometal complex containing a nitroaromatic heterocyclic group of the present invention is shown in Formula I and Formula II. The present invention is the first to link both a nitroaromatic group and a PSMA-targeting group to a metal chelator (such as HBED-CC, DOTA, DOTA(GA)2, NOTA, AAZTA, etc.) and to target a radiometal nuclide, e.g. 68 Ga, 18 F-AlF, 177 Lu, 90 Y, 44 Sc, 225 Ac, 212 Pb, 213 The radioactive metal marker is labeled with Bi, etc. The synergistic effect of the nitroaromatic heterocyclic group in vivo is expected to increase the uptake of the radioactive metal marker by prostate cancer, promoting metabolism in non-target organs and improving the therapeutic efficacy of radiopharmaceuticals against tumors. JPEG2026508753000106.jpg2835JPEG2026508753000107.jpg2145 (wherein the R1 and R2 groups are nitroaromatic heterocyclic groups; L2 is a linking group between the R1 group and L1, where L1 is a linking group between the chelator and the structure PSMA targeting structure; L4 is a linking group between the R2 group and L3, where L3 is a linking group between the chelator and the structure PSMA targeting structure; and ChelatoR1 and ChelatoR2 are chelators or chelating structures.)

Provided herein are a complex for diagnosing non-alcoholic steatohepatitis, use of the complex, and a contrast agent comprising the complex. The complex for diagnosing non-alcoholic steatohepatitis comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator. The complex is capable of binding to an asialoglycoprotein receptor, so that the complex has potential for use as a radiological diagnostic agent.

The present invention relates to zwitterionic metal chelators and their use as imaging agents, diagnostic agents, chemical processing agents, and therapeutic agents. These zwitterionic metal chelators have desirable properties of maximizing solubility in aqueous environments, minimizing non-specific interactions, and retaining targeting ability, resulting in improved performance in a variety of medical, agricultural, and chemical processes. In vivo and medical applications, the zwitterionic metal chelators improve signal-to-background ratios and therapeutic windows compared to other metal chelators, while retaining high stability.

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.

The present invention relates to an engineered microorganism for use in combination with a plant to increase the uptake of metals from a growth medium. In particular, engineering a microorganism to exploit plant hormonal synthesis, suppress stress response, and produce metal chelators is described.

This application belongs to the field of photodetector technology, and relates to a method for preparing a metal-doped A2BX5 crystal, a thin film thereof, and a photodetector. The method for preparing the metal-doped A2BX5 crystal includes providing a first mixed solution comprising AX, BX2, CX2, and a first solvent; subjecting the first mixed solution to a first heat treatment to obtain a second mixed solution; adding a metal chelating agent to the second mixed solution to obtain a third mixed solution; adding a second solvent to the third mixed solution and performing a second heat treatment to obtain a metal-doped A2BX5 crystal, wherein C is doped in the A2BX5 crystal. The metal chelating agent can bind with B ions in the third mixed solution to form a dynamic supramolecular coordination structure, thereby limiting the nucleation rate of B ions and improving the stability of the metal-doped A2BX5 crystal.

Provided herein are peptides and conjugates (e.g., radiopharmaceutical conjugates) having avidity for a somatostatin receptor and uses thereof. The conjugate can comprise a 6-mer peptide, such as a monocyclic 6-mer peptide, a metal chelator, and optionally a linker connecting the peptide to the chelator. The radiopharmaceutical conjugate can further comprise a radionuclide bound to the metal chelator. Further provided herein are methods of preparing the conjugates, and methods of treating cancer by administering the described conjugates to a subject in need thereof.

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.